MedPath

Use of Viscoelastic Tests in the Treatment of Traumatic Induced Coagulopathy: a Pragmatic Randomized Clinical Trial.

Not Applicable
Withdrawn
Conditions
Trauma, Multiple
Massive Hemorrhage
Coagulopathy
Interventions
Procedure: Trauma-induced coagulopathy treatment
Registration Number
NCT03380767
Lead Sponsor
A.O. Ospedale Papa Giovanni XXIII
Brief Summary

Trauma is the leading cause of death in young people. Trauma-induced coagulopathy (TIC) encompasses several aspects of traumatic bleeding. Monitoring of coagulopathy comprises use of Point-of-Care (POC) methods, such as thromboelastography (TEG) or Thromboelastometry (ROTEM) and conventional laboratory assays (platelet count, fibrinogen level, and PT or INR).

POC tests are thought to have a better performance on mortality and bleeding control than conventional tests. The aim of this study is to compare POC and conventional assays with plasma consumption as a primary outcome and 28 days mortality as a secondary one.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

all adult (> 18 years old) trauma patients treated in our Emergency Department with a TASH score > 18

Exclusion Criteria
  • dead on arrival
  • no blood product administered after randomization

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Conventional groupTrauma-induced coagulopathy treatmentIn this group, patients will be treated according to the information gathered by conventional laboratory assays (platelet count, fibrinogen level, PT or INR and d dimer for fibrinolysis)
POC groupTrauma-induced coagulopathy treatmentIn this group, patients will be treated according to the information gathered by TEG or ROTEM assays.
Primary Outcome Measures
NameTimeMethod
Fresh frozen plasma consumption3 years

In the POC group plasma consumption is estimated 20% less than in conventional assays group

Secondary Outcome Measures
NameTimeMethod
Mortality28 days

28 days mortality

Trial Locations

Locations (1)

Ospedale Papa Giovanni XXIII

🇮🇹

Bergamo, BG, Italy

© Copyright 2025. All Rights Reserved by MedPath